Cargando…
A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with (68)Ga-labeled PD-L1 targeted nanobody
Although immunotherapy has achieved great clinical success in clinical outcomes, especially the anti-PD-1 or anti-PD-L1 antibodies, not all patients respond to anti-PD-1 immunotherapy. It is urgently required for a clinical diagnosis to develop non-invasive imaging meditated strategy for assessing t...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8148448/ https://www.ncbi.nlm.nih.gov/pubmed/33910164 http://dx.doi.org/10.18632/aging.202981 |
_version_ | 1783697840329981952 |
---|---|
author | Qin, Songbing Yu, Yang Guan, Hui Yang, Yanling Sun, Fenghao Sun, Yan Zhu, Jiaxing Xing, Ligang Yu, Jinming Sun, Xiaorong |
author_facet | Qin, Songbing Yu, Yang Guan, Hui Yang, Yanling Sun, Fenghao Sun, Yan Zhu, Jiaxing Xing, Ligang Yu, Jinming Sun, Xiaorong |
author_sort | Qin, Songbing |
collection | PubMed |
description | Although immunotherapy has achieved great clinical success in clinical outcomes, especially the anti-PD-1 or anti-PD-L1 antibodies, not all patients respond to anti-PD-1 immunotherapy. It is urgently required for a clinical diagnosis to develop non-invasive imaging meditated strategy for assessing the expression level of PD-L1 in tumors. In this work, a (68)Ga-labeled single-domain antibody tracer, (68)Ga-NOTA-Nb109, was designed for specific and noninvasive imaging of PD-L1 expression in an MC38 tumor-bearing mouse model. Comprehensive studies including Positron Emission Tomography (PET), biodistribution, blocking studies, immunohistochemistry, and immunotherapy, have been performed in differences PD-L1 expression tumor-bearing models. These results revealed that (68)Ga-NOTA-Nb109 specifically accumulated in the MC38-hPD-L1 tumor. The content of this nanobody in MC38 hPD-L1 tumor and MC38 Mixed tumor was 8.2 ± 1.3, 7.3 ± 1.2, 3.7 ± 1.5, 2.3 ± 1.2%ID/g and 7.5 ± 1.4, 3.6 ± 1.7, 1.7 ± 0.6, 1.2 ± 0.5%ID/g at 0.5, 1, 1.5, 2 hours post-injection, respectively. (68)Ga-NOTA-Nb109 has the potential to further noninvasive PET imaging and therapy effectiveness assessments based on the PD-L1 status in tumors. To explore the possible synergistic effects of immunotherapy combined with chemotherapy, MC38 xenografts with different sensitivity to PD-L1 blockade were established. In addition, we found that PD-1 blockade also had efficacy on the PD-L1 knockout tumors. RT-PCR and immunofluorescence analysis were used to detect the expression of PD-L1. It was observed that both mouse and human PD-L1 expressed among three types of MC38 tumors. These results suggest that PD-L1 on tumor cells affect the efficacy, but it on host myeloid cells might be essential for checkpoint blockade. Moreover, anti–PD-1 treatment activates tumor-reactive CD103(+) CD39(+) CD8+T cells (TILs) in tumor microenvironment. |
format | Online Article Text |
id | pubmed-8148448 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Impact Journals |
record_format | MEDLINE/PubMed |
spelling | pubmed-81484482021-05-26 A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with (68)Ga-labeled PD-L1 targeted nanobody Qin, Songbing Yu, Yang Guan, Hui Yang, Yanling Sun, Fenghao Sun, Yan Zhu, Jiaxing Xing, Ligang Yu, Jinming Sun, Xiaorong Aging (Albany NY) Research Paper Although immunotherapy has achieved great clinical success in clinical outcomes, especially the anti-PD-1 or anti-PD-L1 antibodies, not all patients respond to anti-PD-1 immunotherapy. It is urgently required for a clinical diagnosis to develop non-invasive imaging meditated strategy for assessing the expression level of PD-L1 in tumors. In this work, a (68)Ga-labeled single-domain antibody tracer, (68)Ga-NOTA-Nb109, was designed for specific and noninvasive imaging of PD-L1 expression in an MC38 tumor-bearing mouse model. Comprehensive studies including Positron Emission Tomography (PET), biodistribution, blocking studies, immunohistochemistry, and immunotherapy, have been performed in differences PD-L1 expression tumor-bearing models. These results revealed that (68)Ga-NOTA-Nb109 specifically accumulated in the MC38-hPD-L1 tumor. The content of this nanobody in MC38 hPD-L1 tumor and MC38 Mixed tumor was 8.2 ± 1.3, 7.3 ± 1.2, 3.7 ± 1.5, 2.3 ± 1.2%ID/g and 7.5 ± 1.4, 3.6 ± 1.7, 1.7 ± 0.6, 1.2 ± 0.5%ID/g at 0.5, 1, 1.5, 2 hours post-injection, respectively. (68)Ga-NOTA-Nb109 has the potential to further noninvasive PET imaging and therapy effectiveness assessments based on the PD-L1 status in tumors. To explore the possible synergistic effects of immunotherapy combined with chemotherapy, MC38 xenografts with different sensitivity to PD-L1 blockade were established. In addition, we found that PD-1 blockade also had efficacy on the PD-L1 knockout tumors. RT-PCR and immunofluorescence analysis were used to detect the expression of PD-L1. It was observed that both mouse and human PD-L1 expressed among three types of MC38 tumors. These results suggest that PD-L1 on tumor cells affect the efficacy, but it on host myeloid cells might be essential for checkpoint blockade. Moreover, anti–PD-1 treatment activates tumor-reactive CD103(+) CD39(+) CD8+T cells (TILs) in tumor microenvironment. Impact Journals 2021-04-27 /pmc/articles/PMC8148448/ /pubmed/33910164 http://dx.doi.org/10.18632/aging.202981 Text en Copyright: © 2021 Qin et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Qin, Songbing Yu, Yang Guan, Hui Yang, Yanling Sun, Fenghao Sun, Yan Zhu, Jiaxing Xing, Ligang Yu, Jinming Sun, Xiaorong A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with (68)Ga-labeled PD-L1 targeted nanobody |
title | A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with (68)Ga-labeled PD-L1 targeted nanobody |
title_full | A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with (68)Ga-labeled PD-L1 targeted nanobody |
title_fullStr | A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with (68)Ga-labeled PD-L1 targeted nanobody |
title_full_unstemmed | A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with (68)Ga-labeled PD-L1 targeted nanobody |
title_short | A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with (68)Ga-labeled PD-L1 targeted nanobody |
title_sort | preclinical study: correlation between pd-l1 pet imaging and the prediction of therapy efficacy of mc38 tumor with (68)ga-labeled pd-l1 targeted nanobody |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8148448/ https://www.ncbi.nlm.nih.gov/pubmed/33910164 http://dx.doi.org/10.18632/aging.202981 |
work_keys_str_mv | AT qinsongbing apreclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody AT yuyang apreclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody AT guanhui apreclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody AT yangyanling apreclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody AT sunfenghao apreclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody AT sunyan apreclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody AT zhujiaxing apreclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody AT xingligang apreclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody AT yujinming apreclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody AT sunxiaorong apreclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody AT qinsongbing preclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody AT yuyang preclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody AT guanhui preclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody AT yangyanling preclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody AT sunfenghao preclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody AT sunyan preclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody AT zhujiaxing preclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody AT xingligang preclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody AT yujinming preclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody AT sunxiaorong preclinicalstudycorrelationbetweenpdl1petimagingandthepredictionoftherapyefficacyofmc38tumorwith68galabeledpdl1targetednanobody |